linical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesion

Author(s)

Martins, Mariana Bonjiorno ^[1] ; Batista, Fernando de Assis ^[1] ; Marcello, Marjory Alana ; Bufalo, Natassia Elena ^[1] ; Peres, Karina Colombera ^[1] ; Morari, Elaine Cristina ^{[1, 2]} ; Soares, Fernando Augusto ^{[3, 4]} ; Vassallo, Jose ^[5] ; Ward, Laura Sterian ^[1]

Affiliation

^[1] Univ Campinas FCM Unicamp, Fac Med Sci, Lab Canc Mol Genet, 126 Tessalia Vieira Camargo, BR-13083887 Campinas, SP - Brazil

^[2] State Univ Roraima, Dept Biol & Hlth Sci, Boa Vista, Parana - Brazil

^[3] Univ Sao Paulo, Sch Dent, Dept Gen Pathol, Sao Paulo - Brazil

^[4] Rede Dor Hosp Network, Idor Res Inst, Div Pathol, Sao Paulo - Brazil

^[5] Univ Campinas UNICAMP, Fac Med Sci FCM, CIPED, Lab Invest & Mol Pathol, Campinas, SP - Brazil

• Document type: Journal article
• Source: ANNALS OF DIAGNOSTIC PATHOLOGY; v. 53, AUG 2021.
• Web of Science Citations: 0

Abstract

In order to investigate the possible correlation between p53 and MDM2 co-expression with clinicopathological features of differentiated thyroid cancer (DTC) and its use as diagnostic and/or prognostic markers, we used immunohistochemistry to evaluate 317 thyroid samples including 208 DTC and 94 benign nodules, in addition to 15 normal tissues. MDM2 and p53 expression were highly associated (r = 0.7161; p < 0.0001). The co-expression of p53-MDM2 was observed more frequently in malignant lesions (p < 0.0001) and helped characterize follicular patterned lesions distinguishing FVPTC from FA (p < 0.0001) and FVPTC from FTC (p < 0.0001). In addition, p53-MDM2 co-expression was associated with characteristics of less aggressiveness. It was more frequent in patients <= 45 years old (p = 0.0035), with unique tumors (p = 0.0095), tumors <2 cm (p < 0.0001), tumors without extrathyroid invasion (p = 0.0425), without metastasis at evolution (p = 0.0179), and in patients evolving free of disease after treatment (p = 0.0485). We suggest that p53-MDM2 co-expression profile analysis might help establishing diagnostic and determining prognostic of DTC patients. (AU)

• FAPESP's process: 10/08412-8 - PROTEIN EXPRESSION PROFILE OF MAGE A3 IN DIFFERENTIATED THYROID CANCER
• Grantee: Laura Sterian
• Support Opportunities: Regular Research Grants
• FAPESP's process: 10/11769-5 - Analysis of protein profile MAGE A3, p53, MDM2 and KAP-1 in malignancy identification and in the characterization of thyroid follicular lesions
• Grantee: Mariana Bonjiorno Martins
• Support Opportunities: Scholarships in Brazil - Master